Editor's Note

Tricky Transition

Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs

When Dr Reddy’s was granted 180-day exclusivity for fluoxetine, the generic version of anti-depressant Prozac nearly two decades ago in 2001, it was a turning point for the Indian pharma industry. It put India firmly on the map as a serious contender in the generics game. After seeing the windfall profit that the six-month marketing exclusivity generated, Indian companies tasted blood and each of them started to build a pipeline of exclusive launches and generic drugs, and the US became the largest export market for Indian companies.

Analysts started to value the potential pipeline instead of one-time cash flows. What’s more, they wasted no time in extrapolating


You don’t want to be left behind. Do you?

Our work is exclusively for discerning readers. To read our edgy stories and access our archives, you’ve to subscribe